MicroRNA-148a-3p Directly Targets SERPINE1 to Suppress EMT-Mediated Colon Adenocarcinoma Progression

References

• MattiuzziC, LippiG. Current cancer epidemiology. J Epidemiol Glob Health. 2019;9(4):217–222. doi:10.2991/jegh.k.191008.00131854162
   PubMed Web of Science ®Google Scholar
• PhangCW, KarsaniSA, Abd MalekSN. Induction of apoptosis and cell cycle arrest by Flavokawain C on HT-29 human colon adenocarcinoma via enhancement of reactive oxygen species generation, upregulation of p21, p27, and GADD153, and inactivation of inhibitor of apoptosis proteins. Pharmacogn Mag. 2017;13(Suppl 2):S321–s328.28808400
   PubMed Web of Science ®Google Scholar
• BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.30207593
   PubMed Web of Science ®Google Scholar
• HongJ, LuH, MengX, RyuJH, HaraY, YangCS. Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. Cancer Res. 2002;62(24):7241–7246.12499265
   PubMed Web of Science ®Google Scholar
• RoncucciL, MarianiF. Prevention of colorectal cancer: how many tools do we have in our basket?Eur J Intern Med. 2015;26(10):752–756.26499755
   PubMed Web of Science ®Google Scholar
• AzarI, EsfandiarifardS, SinaiP, MehdiS. Colon cancer survival in the US Department of Veterans Affairs by race and stage: 2001 through 2009. Cancer. 2018;124(13):2858.29710403
   PubMed Web of Science ®Google Scholar
• TsukudaK, TaninoM, SogaH, ShimizuN, ShimizuK. A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma. Biochem Biophys Res Commun. 2000;278(3):653–658.11095964
   PubMed Web of Science ®Google Scholar
• TsimberidouAM. Targeted therapy in cancer. Cancer Chemother Pharmacol. 2015;76(6):1113–1132.26391154
   PubMed Web of Science ®Google Scholar
• HerzigDO, TsikitisVL. Molecular markers for colon diagnosis, prognosis and targeted therapy. J Surg Oncol. 2015;111(1):96–102.25297801
   PubMed Web of Science ®Google Scholar
• BinderBR, ChristG, GruberF, et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci. 2002;17:56–61.11909993
   PubMedGoogle Scholar
• MazzoccoliG, PazienzaV, PanzaA, et al. ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer. J Cancer Res Clin Oncol. 2012;138(3):501–511.22198637
   PubMed Web of Science ®Google Scholar
• PlacencioVR, DeClerckYA. Plasminogen Activator Inhibitor-1 in Cancer: rationale and Insight for Future Therapeutic Testing. Cancer Res. 2015;75(15):2969–2974.26180080
   PubMed Web of Science ®Google Scholar
• RokavecM, OnerMG, LiH, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014;124(4):1853–1867.24642471
   PubMed Web of Science ®Google Scholar
• BergerDH. Plasmin/plasminogen system in colorectal cancer. World J Surg. 2002;26(7):767–771.11965442
   PubMed Web of Science ®Google Scholar
• LujambioA, LoweSW. The microcosmos of cancer. Nature. 2012;482(7385):347–355.22337054
   PubMed Web of Science ®Google Scholar
• WangX, LiangZ, XuX, et al. miR-148a-3p represses proliferation and EMT by establishing regulatory circuits between ERBB3/AKT2/c-myc and DNMT1 in bladder cancer. Cell Death Dis. 2016;7(12):e2503.27906180
   PubMed Web of Science ®Google Scholar
• WuT, QuL, HeG, et al. Regulation of laryngeal squamous cell cancer progression by the lncRNA H19/miR-148a-3p/DNMT1 axis. Oncotarget. 2016;7(10):11553–11566.26872375
   PubMedGoogle Scholar
• GinzingerDG. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol. 2002;30(6):503–512.12063017
   PubMed Web of Science ®Google Scholar
• GargM. Epithelial plasticity, autophagy and metastasis: potential modifiers of the crosstalk to overcome therapeutic resistance. Stem Cell Rev Rep. 2020.
   PubMed Web of Science ®Google Scholar
• NaTY, SchectersonL, MendonsaAM, GumbinerBM. The functional activity of E-cadherin controls tumor cell metastasis at multiple steps. Proc Natl Acad Sci U S A. 2020;117(11):5931–5937.32127478
   PubMed Web of Science ®Google Scholar
• ThieryJP, AcloqueH, HuangRY, NietoMA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890.19945376
   PubMed Web of Science ®Google Scholar
• NauseefJT, HenryMD. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?Nat Rev Urol. 2011;8(8):428–439.21691304
   PubMed Web of Science ®Google Scholar
• KimMS, LeeWS, JeongJ, KimSJ, JinW. Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer. Oncotarget. 2015;6(37):40158–40171.26515594
   PubMedGoogle Scholar
• LamouilleS, XuJ, DerynckR. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196.24556840
   PubMed Web of Science ®Google Scholar
• BinefaG, Rodriguez-MorantaF, TeuleA, Medina-HayasM. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. 2014;20(22):6786–6808.24944469
   PubMed Web of Science ®Google Scholar
• Klimczak-BitnerAA, KordekR, BitnerJ, MusialJ, SzemrajJ. Expression of MMP9, SERPINE1 and miR-134 as prognostic factors in esophageal cancer. Oncol Lett. 2016;12(5):4133–4138.27895782
   PubMed Web of Science ®Google Scholar
• GuoK, ZhengS, XuY, XuA, ChenB, WenY. Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1. Tumour Biol. 2016;37(9):12843–12854.27449037
   PubMedGoogle Scholar
• YangJD, MaL, ZhuZ. SERPINE1 as a cancer-promoting gene in gastric adenocarcinoma: facilitates tumour cell proliferation, migration, and invasion by regulating EMT. J Chemother. 2019;31(7–8):408–418.31724495
   PubMed Web of Science ®Google Scholar
• TomitaT, IeguchiK, CoinF, et al. ZFC3H1, a zinc finger protein, modulates IL-8 transcription by binding with celastramycin A, a potential immune suppressor. PLoS One. 2014;9(9):e108957.25268596
   PubMed Web of Science ®Google Scholar
• SongB, DuJ, SongDF, RenJC, FengY. Dysregulation of NCAPG, KNL1, miR-148a-3p, miR-193b-3p, and miR-1179 may contribute to the progression of gastric cancer. Biol Res. 2018;51(1):44.30390708
   PubMed Web of Science ®Google Scholar
• JiliS, EryongL, LijuanL, ChaoZ. RUNX3 inhibits laryngeal squamous cell carcinoma malignancy under the regulation of miR-148a-3p/DNMT1 axis. Cell Biochem Funct. 2016;34(8):597–605.27859417
   PubMed Web of Science ®Google Scholar
• JacobH, StanisavljevicL, StorliKE, HestetunKE, DahlO, MyklebustMP. Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer. Oncotarget. 2017;8(50):87837–87847.29152124
   PubMedGoogle Scholar
• WangW, DongJ, WangM, YaoS, ZhangS. miR‑148a‑3p suppresses epithelial ovarian cancer progression primarily by targeting c‑Met. Oncol Lett. 2018;15(5):6131–6136.29616095
   PubMed Web of Science ®Google Scholar
• BhattacharyaS, ChalkAM, NgAJ, et al. Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death. Oncogene. 2016;35(40):5282–5294.27041566
   PubMed Web of Science ®Google Scholar